Red Glead Discovery

Executive Summary

Red Glead Discovery is a Swedish contract research organization (CRO) based in Lund, providing integrated drug discovery services focused on small molecules, peptides, and macrocycles. Founded in 2016, the company offers a comprehensive suite of services including analytical chemistry, custom synthesis, in vitro profiling, and project management, serving pharmaceutical and biotech partners. With a lean team of 1-10 employees, Red Glead Discovery positions itself as a flexible and specialized partner capable of advancing projects from concept to delivery. As a private entity with no disclosed funding or valuation, the company operates in the competitive CRO market, leveraging its expertise in oncology and small molecules to differentiate itself. Its reliance on client engagements makes growth dependent on securing new contracts and expanding its service portfolio. The company's modest scale allows for agility but limits its capacity to handle large-scale programs independently.

Upcoming Catalysts (preview)

• TBDSecuring a major drug discovery contract with a pharmaceutical partner60% success
• TBDExpansion of service capabilities (e.g., in vivo pharmacology or ADME)50% success